First-In-Man Dose Escalation Study of Aspirin® Inhaled For The Clinical Development of A New Antiviral Treatment of Resistant Influenza

First-In-Man Dose Escalation Study of Aspirin® Inhaled For The Clinical Development of A New Antiviral Treatment of Resistant Influenza

Introduction D, L-lysine acetylsalicylate (ASA) glycine (LASAG, Aspirin i.v.®) has antiviral activity including resistant viral strains: inhalation of nebulized LASAG leads to dose-dependent lung virus titer reduction in mice, decreases disease severity and weight loss.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical therapeutics 2015-08, Vol.37 (8), p.e155-e155
Hauptverfasser: Nagelschmitz, J, Scheerans, Ch, Kraetzschmar, J, von Degenfeld, G, Müllinger, B, Wensing, G
Format: Artikel
Sprache:eng
Schlagworte:
Influenza
Internal Medicine
Laboratories
Medical Education
Mortality
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Introduction D, L-lysine acetylsalicylate (ASA) glycine (LASAG, Aspirin i.v.®) has antiviral activity including resistant viral strains: inhalation of nebulized LASAG leads to dose-dependent lung virus titer reduction in mice, decreases disease severity and weight loss.
ISSN:0149-2918
1879-114X
DOI:10.1016/j.clinthera.2015.05.443